PRMT5 and non-Hodgkin lymphoma: Two PRMT5 inhibitors (GSK3326595 and JNJ-64619178) inhibit the growth of melanoma tumours in murine model and are currently being investigated as the treatment of solid tumours, Non-Hodgkin’s lymphoma and breast cancer [111–113].